EPT Disclosure

RNS Number:5572E
Deutsche Bank AG London
14 June 2006

                                  FORM 38.5(a)

                 DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS
                      WITH RECOGNISED INTERMEDIARY STATUS
                      DEALING IN A CLIENT-SERVING CAPACITY
                      (Rule 38.5(a) of the Takeover Code)



1.         KEY INFORMATION


Name of exempt principal trader                Deutsche Bank AG London

Company dealt in                               Cambridge Antibody Technology Group Plc   

Class of relevant security to which the        Ordinary
dealings being disclosed relate (Note 1)

Date of dealing                                13/06/2006






2.         DEALINGS (Note 2)



(a)        Purchases and sales


Total number of securities purchased   Highest price paid (Note 3)           Lowest price paid (Note 3)


25,200                                 #13.075                               #13.07




Total number of securities sold        Highest price received (Note 3)       Lowest price received (Note 3)






(b)        Derivatives transactions (other than options)


Product name,         Long/short (Note 4)       Number of securities (Note 5)        Price per unit (Note 3)
e.g. CFD

CFD                   Long                      25,000                               #13.07
CFD                   Long                      200                                  #13.075





(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying


Product name,         Writing, selling, Number of securities  Exercise   Type, e.g.      Expiry     Option money
                      purchasing,       to which the option              American,       Date       paid/received per
e.g. call option      varying etc.      relates (Note 5)      price      European etc.              unit (Note 3)





(ii)        Exercising


Product name, e.g. call option         Number of securities                  Exercise price per unit (Note 3)















3.         OTHER INFORMATION



Agreements, arrangements or understandings relating to options or derivatives




Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which any
derivative referred to on this form is referenced.  If none, this should be
stated.


NONE








Date of disclosure                                   14/06/2006

Contact name                                         Kelly-Jade Ledwich

Telephone number                                     020 7545 7804

Name of offeree/offeror with which connected         AstraZeneca Plc

Nature of connection (Note 6)                        Adviser to the offeror






Notes



The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk









                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

EMMSFEFFLSMSEFM